Table 2.

Genetic variants associated with cisplatin-induced hearing loss

SNP	Allele	Initial cohorta (n = 162)			P-value	Replication cohort (n = 155)			P-value	Combined cohort (n = 317)			P-value	P-valueb
		106 cases, 56 controls				87 cases, 68 controls				193 cases, 124 controls
		Case	Ctrl	OR (95% CI)		Case	Ctrl	OR (95% CI)		Case	Ctrl	OR (95% CI)
TPMT
rs12201199	A	28	1	16.9 (2.3–125.9)	0.00022	21	3	6.1 (1.8–20.9)	0.0013	49	4	8.9 (3.2–24.9)	8.7 × 10−7	4.0 × 10−5
	T	184	111			153	133			337	244
rs1142345	G	19	1	10.9 (1.4–82.7)	0.0017	16	3	4.5 (1.3–15.7)	0.011	35	4	6.1 (2.1–17.3)	0.00014	0.00039
	A	193	111			158	133			351	244
rs1800460	A	16	0	18.0 (1.1–302.7)	0.0031	13	3	3.6 (1.0–12.8)	0.038	29	3	6.6 (2.0–21.8)	0.00043	0.00073
	G	196	110			161	133			357	243
COMT
rs4646316	G	176	74	2.5 (1.5–4.3)	0.00055	141	104	1.3 (0.8–2.3)	0.33	317	178	1.8 (1.2–2.6)	0.0021	0.0068
	A	36	38			33	32			69	70
rs9332377	A	36	4	5.5 (1.9–16.0)	0.00018	38	23	1.4 (0.8–2.4)	0.28	74	27	1.9 (1.2–3.1)	0.0054	0.043
	G	176	108			136	113			312	221
ABCC3
rs1051640	G	182	83	2.1 (1.2–3.8)	0.0092	146	101	1.8 (1.0–3.3)	0.036	328	184	2.0 (1.3–2.9)	0.00078	0.0033
	A	30	29			28	35			58	64

Boldface numbers are results more significant in current combined cohort than in previous combined cohort (ref. 9).

CI, confidence interval; Ctrl, control; OR, odds ratio; SNP, single-nucleotide polymorphism.

^aResults from the initial combined cohort (ref. 9) compared with the current replication cohort as well as all cohorts combined.

^bAdjusted for age, vincristine treatment, germ-cell tumor, and cranial irradiation.